Erythema multiforme to saquinavir;Erytheme polymorphe au saquinavir

Annales de Dermatologie et de Venereologie

Volumn 125, Issue 1, 1998, Pages 42-43

  Garat, H ^a  

^a Département de Dermatologie Vénéréologie et Allergologie

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIDANOSINE; LAMIVUDINE; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PALATE; SKIN DEFECT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMICALLY INDUCED DISORDER; DRUG CONTRAINDICATION; MOUTH DISEASE; MOUTH MUCOSA; PATHOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ERYTHEMA MULTIFORME; HIV PROTEASE INHIBITORS; HUMANS; MALE; MOUTH DISEASES; MOUTH MUCOSA; PALATE; SAQUINAVIR;

EID: 0031615917     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Barlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996;124:1086-8.
2. Noble S, Faulds D. Saquinavir: a review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996;52:93-112.
3. Moyle G. Saquinavir a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996;J: 155-67.
4. Moyle G, Gazzard B. Current knowledge and future prospects for the use of H1V protease inhibitors. Drugs 1996;51:701-12.
5. Boudes P, Geiger JM. Les inhibiteurs de la protéase du VIH: revue générale. Thérapie 1996; 51:319-25.
6. Kitchen V, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J et al. Safety and activity of Saquinavir in HIV infection. Lancet 1995;345:9525.
7. Kitchen V, Skinner C, Sedgwick A, Bragman K, Pinching AJ, Weber J et al. A phase I-II dose ranging study of the safety and activity of Ro 31-8959 (HIV proteinase inhibitor) in asymptomatic or midly symptomatic HIV-infection. IX International conference on AIDS, Berlin, June 7-11, 1993.
8. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ et al. The effect of high-dose Saquinavir on viral load and CD4 + T-cell count in HIV- infected patients. Ann Intern Med 1996;124:1039-50.
9. Shaw TM, Muirhead GJ, Parish N, Mac Lelland GR, Houston AC. Tolerability and pharmacokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor. Br J Clin Piiannnc 1992;3-J.-166.
10. Lewis DA, Brook MG. Erythema multiforme as a presentation of immunodeficiency virus seroconversion illness. lut J STD AIDS 1992:3:56-7.
11. Salomon D, Saurat JH. Erythema multiforme major in a 2-monthold child with human immunodeficiency virus (HIV) infection. Br J Dennatol 1990;127:797-800.
12. Schlicnger RG, Haefeli WE, Bircher A, Leib SL, Lubscher TF. Drug-induced Stevens-Johnson syndrome in patient with AIDS. Schweiz. RunJsch Med Prax 1993;S2:88S-92.
13. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 1985;40:111-8.